Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?

Neurobiology of Aging

Volumn 21, Issue 3, 2000, Pages 441-445

  Praticò, Domenico ^a   Trojanowski, John Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; GENE MUTATION; HYPOTHESIS; IMMUNE RESPONSE; INFLAMMATION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034612148     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(00)00141-X     Document Type: Note

References (36)

1. Clark CM. Clinical manifestations and diagnostic evaluation of patients with Alzheimer's disease. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000. p. 95-114.
2. Hong M, Trojanowski JQ, Lee VM-Y. Tau-based neurofibrillary lesions. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000. p. 161-75.
3. Iwatsubo T. Amyloid deposits and plaque formation. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000. p. 147-56.
4. Masliah E, LiCastro F. Neuronal and synaptic loss, reactive gliosis, microglial response and induction of the complement cascade in Alzheimer's disease. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000. p. 131-46.
5. Zabar Y, Kawas CH. Epidemiology and clinical genetics of Alzheimer's disease. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative dementias: clinical features and pathological mechanisms. New York: McGraw-Hill, 2000. p. 79-94.
6. National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18(suppl. 4):S1-S2.
7. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Zeit Psychiatrie Psy Gerichtliche Med. 64:1907;146-148.
8. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging, 2000;21:383-421.
9. Streit W.J., Walter S.A., Pennel N.A. Reactive microgliosis. Prog Neurobiol. 57:1999;563-581.
10. Eddleston M., Mucke L. Molecular profile of recative astrocytes implications for their role in neurological disease . Neuroscience. 54:1993;15-36.
11. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease a review of 17 epidemiological studies . Neurology. 47:1996;425-432.
12. Aisen P.S., Pasinetti G.M. Glucocorticoids in Alzheimer's disease the story so far . Drugs Aging. 12:1998;1-6.
13. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
14. Aisen P.S., Marin D., Altstiel L., et al. A pilot study of prednisone in Alzheimer's disease. Dementia. 7:1996;201-206.
15. Aisen PS, Davis KL, Berg JD, et al. for the Alzheimer's Disease Cooperative Study. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology 2000;54:588-93.
16. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:1999;197-201.
17. Mackenzie I.R.A., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986-990.
18. Mackenzie I.R.A. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Neurology. 54:2000;732-734.
19. 2. Prostaglandins Leukotrienes Essent Fatty Acids. 47:1992;105-110.
20. Elmquist J.K., Scammel T.E., Saper C.B. Mechanisms of CNS response to systemic immune challenge the febrile response . Trends Neurosci. 20:1997;565-570.
21. Ericsson A., Arias C., Sawchenko P.E. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuity by intravenous interleukin-1 (IL-1). J Neurosci. 17:1997;7166-7179.
22. O'Banion M.K. Cyclooxygenase-2 molecular biology, pharmacology, and neurobiology . Crit Rev Neurobiol. 13:1999;45-82.
23. Guan Y., Chang M., Cho W., et al. Cloning, expression and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol. 273:1997;F18-F26.
24. Komhoff M., Grone H.J., Klein T., Seyberth H.W., Nusing H.W. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney implication for renal function . Am J Physiol. 272:1997;F460-F468.
25. Kaplan M.D., Olschowka J.A., O'Banion M.K. Cyclooxygenase-1 behaves as a delayed response gene in PC-12 cells differentiated by nerve growth factor. J Biol Chem. 272:1997;18534-18537.
26. Kitamura Y., Shimohana S., Koike H., et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-γ in Alzheimer's disease brain. Biochem Biophys Res Commun. 254:1999;582-586.
27. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., O'Banion M.K. Cyclooxygenase-1 in human Alzheimer's and control brain quantitative analysis of expression by microglia and CA3 hippocampal neurons . J Neuropathol Exp Neurol. 58:1999;1135-1146.
28. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
29. Lukiw W.J., Bazan N.G. Cyclooxygenase-2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer's neocortex. J Neurosci Res. 50:1997;937-945.
30. Catella-Lawson F., McAdam B., Morrison B.W., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 289:1999;735-741.
31. Fillit H., Ding W., Buee L., et al. Elevated circulating tumor necrosis factor (TNF) levels in Alzheimer's disease. Neurosci Lett. 129:1991;318-320.
32. Chao C.C., Hu S., Frey W.H., Ala T.A., Tourtellotte W.W., Peterson P.K. Transforming growth factor β in Alzheimer's disease. Clin Diagn Lab Immunol. 1:1994;109-110.
33. Hampel H., Sunderland T., Kotter H.U., et al. Decreased soluble IL-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. Brain Res. 780:1998;356-359.
34. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (London). 391:1998;79-82.
35. Jiang C., Ting A.T., Seed B. PPAR-γ inhibit production of monocyte inflammatory cytokines. Nature (London). 391:1998;82-86.
36. Guenette S.Y., Tanzi R.E. Progress toward valid transgenic mouse models for Alzheimer's disease. Neurobiol Aging. 20:1999;201-211.